Skip to main content
TipRanks
Go Ultimate75% OFF

Avecho Biotechnology Limited (AVE) AI Stock Analysis

14 Followers
AU:AVE

Avecho Biotechnology Limited

(ASX:AVE)

Select Model
Rating:37Underperform
Price Target:AUD 0.01â–¼(-8.33% Downside)
Action:downgraded
Date:11/17/26

The stock scores at the lowest possible level due to severe fundamental and technical weaknesses. The company is deeply unprofitable with a rapidly shrinking equity base, and the stock is in a sustained downtrend across all timeframes. While a recent improvement in cash flow is a minor positive, it is overshadowed by the high risk of financial distress and the lack of any positive valuation or technical signals.

Positive Factors
Improving Revenue GrowthThe acceleration in revenue growth indicates improving commercial traction after a weak prior period. If sustained, stronger top-line momentum can broaden the company’s operating base, support investment in its TPM platform, and improve the potential for future operating leverage.
Negative Factors
Persistent Operating LossesLarge recurring operating and net losses remain the central weakness in the business model, despite better revenue growth. Continued losses can consume capital, restrict reinvestment, and make positive cash generation difficult to sustain unless revenue growth eventually translates into materially better margins.

Avecho Biotechnology Limited (AVE) vs. iShares MSCI Australia ETF (EWA)

-25%0%25%50%75%100%125%150%AU:AVE+20.00%EWA+16.05%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
AUD 46.36M
Dividend Yield
―
Average Volume (3M)
3.84M
Price to Earnings (P/E)
-8.0
Beta (1Y)
1.67
Revenue Growth
-46.59%
EPS Growth
9.09%
Country
Australia
Employees
9
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Avecho Biotechnology Limited Business Overview & Revenue Model

Company Description

Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, France, and India. It operat...

Avecho Biotechnology Limited Financial Statement Overview

Summary

Revenue growth and a recent shift to positive cash flow are encouraging, but persistent deep operating losses, a rapidly deteriorating equity base, and high solvency risk heavily weigh on the score. The lack of progress toward profitability is a critical concern.

Income Statement

25Negative

Balance Sheet

20Very Negative

Cash Flow

55Neutral
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue1.02M1.24M1.13M473.55K1.13M793.60K
Gross Profit543.05K751.29K671.93K-43.80K793.12K507.94K
EBITDA-7.83M-5.87M-2.92M-3.24M-2.11M-2.98M
Net Income-3.66M-4.42M-3.12M-3.44M-2.34M-3.42M
Balance Sheet
Total Assets8.41M7.11M5.00M7.32M3.35M5.25M
Cash, Cash Equivalents and Short-Term Investments6.61M4.66M2.37M5.50M1.47M3.26M
Total Debt227.54K14.47K1.08M175.15K246.07K93.91K
Total Liabilities6.50M5.55M1.73M941.54K920.66K709.36K
Stockholders Equity1.91M1.56M3.27M6.38M2.42M4.54M
Cash Flow
Free Cash Flow-3.48M1.10M-3.97M-3.18M-1.72M-3.30M
Operating Cash Flow-3.48M1.10M-3.97M-3.18M-1.67M-3.10M
Investing Cash Flow-2,0000-15.73K0-53.12K-202.82K
Financing Cash Flow4.16M1.19M854.59K7.22M-78.22K4.69M

Avecho Biotechnology Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

AU:AVE against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
AU:PARAU:PAR47NeutralAUD 153.48M-1.61-1189.87%―53.78%-206.24%
AU:RCEAU:RCE46NeutralAUD 113.19M-7.1484.67%――42.51%
AU:PTXAU:PTX40UnderperformAUD 64.06M-8.12-44.93%――25.27%
AU:IMUAU:IMU39UnderperformAUD 19.24M-0.11-414.10%――-2.15%
AU:IMMAU:IMM38UnderperformAUD 35.38M-0.45-98.86%――-27.73%
AU:AVEAU:AVE37UnderperformAUD 46.36M-8.00-211.39%―-46.59%9.09%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%150%AU:AVEAU:IMUAU:PARAU:IMMAU:PTXAU:RCEDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
AU:AVE and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
AU:AVEAvecho Biotechnology Limited0.010.0020.00%
AU:IMUImugene Ltd0.04-0.27-88.33%
AU:PARParadigm Biopharmaceuticals Ltd.0.24-0.09-25.76%
AU:IMMImmutep Ltd0.02-0.25-91.27%
AU:PTXPrescient Therapeutics Limited0.060.0116.67%
AU:RCERecce Pharmaceuticals Ltd.0.37-0.07-14.94%

Avecho Biotechnology Limited Corporate Events

Avecho reports 40 BIO-Europe partnering meetings

Nov 15, 2026

Avecho presented its insomnia treatment program at BIO-Europe 2026 in Cologne, Germany, and held 40 partnering meetings with potential licensees. The company is pursuing licensing opportunities for its TPM-enhanced CBD soft-gel capsule in territories...

Avecho advances Phase III insomnia trial and expands global CBD patent and licensing strategy

Oct 27, 2026

Avecho has restarted recruitment and dosing for the final stage of its pivotal Phase III clinical trial of a TPM®-enhanced CBD soft-gel capsule for insomnia, aiming for 519 completed participants after a positive interim analysis and a clean safety p...

Avecho names new CFO as late-stage insomnia program advances

Oct 27, 2026

Avecho Biotechnology has appointed Subaraj Subramaniam as Chief Financial Officer, effective 27 October 2026, replacing Melanie Leydin after her seven-year tenure overseeing the company’s finance and governance functions. Subramaniam brings more than...

Avecho says no undisclosed news behind share price spike after ASX query

Oct 21, 2026

Avecho Biotechnology Limited has responded to an ASX price and volume query after its shares rose from A$0.014 to a high of A$0.019 and experienced unusually heavy trading. The company told the exchange it is not aware of any undisclosed information...

Avecho to Spotlight Phase III CBD Insomnia Trial at Canaccord Conference

Oct 12, 2026

Avecho Biotechnology will present at the Canaccord Drug and Device Conference in Noosa, where CEO Dr Paul Gavin is set to update investors on the company’s Phase III trial of its TPM-enhanced CBD soft-gel capsule for insomnia and outline planned acti...

Avecho Advances Phase III CBD Insomnia Trial Ahead of ASX SMIDcaps Presentation

Sep 22, 2026

Avecho Biotechnology Limited will present at the ASX SMIDcaps Conference, where CEO Dr Paul Gavin will update investors on the company’s Phase III trial of its CBD TPM soft-gel capsule for insomnia and outline planned activities over the next 12 to 1...

Avecho resumes final recruitment for pivotal Phase III insomnia trial

Aug 31, 2026

Avecho Biotechnology has restarted recruitment for the final stage of its pivotal Phase III clinical trial of a TPM-enhanced cannabidiol soft-gel capsule targeting insomnia in adults. The multi-centre, randomised, double-blind, placebo-controlled stu...

Avecho Issues 7.9 Million Unquoted Options Under Employee Incentive Scheme

Aug 27, 2026

Avecho Biotechnology Limited has notified the market of the issue of 7,923,243 unquoted options under its employee incentive scheme, with various exercise prices and expiry dates. The move underscores the company’s continued use of equity-based compe...

Avecho hires senior dealmaker to drive CBD insomnia capsule partnerships

Aug 24, 2026

Avecho Biotechnology has appointed senior international biopharmaceutical executive Eve Williamson as a strategic business development consultant to bolster its global partnering and licensing efforts. Williamson, formerly Vice President and Global H...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 17, 2026